SLC5A2 and heart failure: As such, the absence of significant improvement in cardiac parameters with dapagliflozin should not be interpreted as an indication that this compound does not prevent hospitalization for heart failure in the clinical setting especially considering the positive findings of its phase 2/3 program [50], post-marketing studies [51] and the effects of other members of the SGLT2 inhibitory class [52] along with supporting basic and translational research studies [53–55].